medigraphic.com

2015, Number 2

<< Back Next >>

Revista Cubana de Angiología y Cirugía Vascular 2015; 16 (2)

The empiric and prudent anti-microbial therapy used in the patients with vascular peripheral disease

Fleitas EAS

Language: Spanish
References: 31
Page: 190-204
PDF size: 150.83 Kb.


ABSTRACT

Introduction: inadequate use of the antimicrobial drugs has brought about increase microorganism resistance, the rise of hospital costs and poor quality of the rendered services.
Objective: to advise on the rational therapeutic policy for the use of antimicrobials, mainly when used empirically.
Data source: literature review conducted from 2000 to 2014 MedLine, Hinari, Cochrane PubMed databases and in leading journals that publish articles of interest. The following keywords were used: antibiotics, bacterial resistance and antimicrobial treatment. Prospective, retrospective, clinical, epidemiological cohort studies as well as literature reviews and clinical assays were all consulted.
Data synthesis: this paper provided some useful information in medical practice, as well as some procedures and methods created by teams of experts on this topic and international consensus on the theme. One must take into account whenever possible exudates for culturing and antibiogram that show the likely antimicrobials to which the microorganism is sensitive, and select the most appropriate based on its narrowest spectrum effectiveness, less adverse effects and the most economic to be used at the right dosage and for the required time depending on weight, size, age and renal or liver conditions of the patient. Additionally, the antimicrobial should be applied through the simplest and less risky way of administration in order to achieve the best results of treatment at the shortest term.
Conclusions: It is suggested that rational and prudent antimicrobial therapy should be used in patients, mainly if it is empirically applied. Its effect is to increase efficacy of drugs for patients suffering frequent vascular infections.


REFERENCES

  1. Molejón García M. Estrategias de la alianza para el uso prudente de antibióticos en cuba. MEDISAN. 2013 [citado 1 Dic 2013];17(10). Disponible en: http://bvs.sld.cu/revistas/san/vol17_10_13/san011710.pdf

  2. March García JR. Secciones y grupos de trabajos de la SEACV. En Historia de la SEACV (50º aniversario: 1959-2009). Sociedad Española de Angiología y Cirugía vascular. Ed. Glosa SA. Barcelona, 2010:131-142.

  3. Blanes Mompo JI, Lozano F, Clará A, Alcalá D, Doiz E, Merino R, González del Castillo J, Barberán J, Zaragoza R, García Sánchez JE. Consensus document on treatment of infections in diabetic foot. Rev Esp Quimioter 2011;24(4):233-62.

  4. Sotto A, Richard JL, Combescure C, Jourdan N, Schuldiner S, Bouziges N, et al. Beneficial effects of implementing guidelines on microbiology and costs of infected diabetic foot ulcers. Diabetologia. 2010;53:2249-2255.

  5. Eleftheriadou I, Tentolouris N, Argiana V, Jude E, Boulton AJ. Methicillin-resistant Staphylococcus aureus in diabetic foot infections. Drugs. 2010;70:1785-1797.

  6. Appleman MD, Citron DM. Efficacy of vancomicin and daptomycin against Staphylococcus aureus isolates collected over 29 years. Diagn Microbiol Infect Dis. 2010;66:441-444.

  7. Shakil S, Khan AU. Infected foot ulcers in male and female diabetic patients: a clinico-bioinformative study. Ann Clin Microbiol Antimicrob. 2010;9:2.

  8. Chakraborti C, Le C, Yanofsky A. Sensitivity of superficial cultures in lower extremity wounds. J Hosp Med 2010;5:415-420.

  9. Joseph WS, Lipsky BA. Medical therapy of diabetic foot infections. J Vasc Surg. 2010;52(3 Suppl):67-71.

  10. Pola BF, Patricio NM, Pohlenz A, Otaíza O. Costo de las infecciones intrahospitalarias en hospitales chilenos de alta y mediana complejidad. Rev Chilena Infect. 2003;20(4):285-90.

  11. Fisher TK, Wolcott R, Wolk DM, Bharara M, Kimbriel HR, Armstrong DG. Diabetic foot infections: A need for innovative assessments. Int J Low Extrem Wounds 2010;9:31-36.

  12. Richard JL, Sotto A, Lavigne JP. New insights in diabetic foot infection. World J Diabetes 2011;2:24-32.

  13. Garza Velasco R, Zúñiga Rangel O, Perea Mejía LM. La importancia clínica actual de staphylococcus aureus en el ambiente intra-hospitalario. Educ Quím. 2013 [citado 1 dic 2013];24(1):8-13. disponible en: http://www.educacionquimica.info/search_volume.php?id_revista=120

  14. Dinh T, Snyder G, Veves A. Current techniques to detect foot infection in the diabetic patient. Int J Low Extrem Wounds 2010;9:24-30.

  15. Puchades Gimeno F, Valero Domenech A, Zaragoza Crespo R. Biomarcadores en sepsis. En M Borges, R. Ferrer, R. Zaragoza Libro blanco 2010 Actualizaciones en sepsis en el paciente crítico. Vol 1. Ed. Edikamed. Barcelona 2011. p. 21-35.

  16. Dellit TH, Owens RC, Mc Gowan JE, Gerding DN, Weinstein RA, Burke JP, et al. Infectious diseases Society of America and the Society for Health-care Epidemiology of America Guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44:159-77.

  17. Bouadma L, Luyt CE, Tubach F, Cracco C, Alvarez A, Schwebel C, et al; PRORATA trial group. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010;375:463-74.

  18. NICE Guideline, 2010. Diabetic foot problems: inpatient management of diabetic foot problems. [citado 27 Dic 2013]. Disponible en: http://www.nice.org.uk/guidance/index.jspaction=folder (Septiembre 2010).

  19. Dellinger EP, Gross PA, Barret TL, Krause PJ, Martone WJ, Mc Gowan JE, et al. Quality standard for antimicrobial prophylaxis in surgical procedures. Clin Infect Dis. 1994;18(3):422-7.

  20. Cisneros JM. Poor antimicrobial training of clinicians in Spain. Enferm Infect Microbiol Clin. 2013 [citado 1 Dic 2013];31:197–203. Disponible en: http://www.ecdc.europa.eu

  21. Rincón S, Panesso D, Díaz l, Carvajal LP, Reyes J, Munita JM, Arias CA. Resistencia a antibióticos de última línea en cocos Gram positivos: la era posterior a la Vancomicina. Biomédica. 2014 [citado 1 Dic 2013];34(Supl 1):191-208. Disponible en: http://dx.doi.org/10.7705/biomedica.v34i0.2210

  22. Cainzos M, Lozano F, Dávila D. Asociación española de cirujanos. Protocolos recomendables de profilaxis antibiótica. Rev Cir Esp. 1996;59(1):3-6.

  23. Rodríguez-Baño J, Pardo Pardo JR, Álvarez Rocha L, Asensio A, Calbo E, Cerce- Nado E, et al. Programas de optimización de uso de antimicrobianos (PROA) en hospitales españoles: documento de consenso GEIH-SEIMC, SEFH y SEMPSPH. Enferm Infecc Microbiol Clin. 2012;30(22):1-23.

  24. Mensa J, Cratel JM, Jiménez de Aqnta MT, Prats G, Domínguez-Gil A. Guía de terapia antimicrobiana. Duodécima edición. Barcelona: Edición Mason; 2002.

  25. Cisneros JM, Pérez-Moreno A, Gil-Navarro MV. Política de antibióticos. Comisión de infecciones y uso de antimicrobianos. Enferm Infecc Microbiol Clin. 2014 [citado 9 Ene 2015];32(8):533–6. Disponible en: http://www.seimc.org/contenidos/documentoscientificos/eimc/seimc_eimc_v32n08p5 33a536.pdf

  26. González Alemán M. Resistencia antimicrobiana, una amenaza mundial. Rev Cubana Pediatr. 2013 [citado 1 Dic 2014];85(4):414-7. Disponible en: http://scielo.sld.cu/pdf/ped/v85n4/ped01413.pdf

  27. Quirós Enríquez M, Fernández Ruíz DR, Barrios Romero B, Milián Vázquez PM, Cisneros Napóles Y, Noa Justafé L. Las oxazolidinonas como alternativa en el tratamiento del staphylococcus aureus multi-resistente. MEDISUR. 2013 [citado 27 Dic 2013];11(2):159-66. Disponible en: http://medisur.sld.cu/index.php/medisur/article/view/2115

  28. Cantona B, Ruíz-Garbajosa P. Formación médica continuada: Infección nosocomial. fundamentos y actuación clínica. Infecciones causadas por bacterias Gram positivas multi-resistentes (staphylococcus aureus y enterococcus spp). Enferm Infecc Microbiol Clin. 2013;31(8):543-51.

  29. Traunmüller F, Schintler MV, Metzler J, Spendel S, Mauric O, Popovic M, et al. Soft tissue and bone penetration abilities of daptomycin in diabetic patients with bacterial foot infections. J Antimicrob Chemother. 2010;65:1252-7.

  30. Matsumoto K, Takeshita A, Ikawa K, Shigemi A, Yaji K, Shimodozono Y, et al. Higher Linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction. Int J Antimicrob Agents. 2010;36:179-81.

  31. Rogers LC, Andros G, Caporusso J, Harkless LB, Mills JL, Armstrong DG. Toe and flow: Essential components and structure of the amputation prevention team. J Vasc Surg. 2010;52:23s-27s.




2020     |     www.medigraphic.com